Urologic Clinics of North America 2003: Vol 31 Index

25 Pages·2003·6.3 MB·English

UROLOGIC
CLINICS
ELSEVIER of North America
SAUNDERS Urol Clin N Am 31 ( 2004) 801 R74
Cumulative Index 2004
Volume 31
February ADVANCES IN URETEROSCOPY, pages 1-194
May PREVENTIVE MEDICINE AND MEN’ S HI Al TH, pages 195—388
August PEDIATRIC UROLOGY FOR THE GI NERAL UROLOGIST, pages 389-652
November ROBOTIC UROLOGIC SURGERY, pages 653-824
Page numbers of article titles are in boldface type
Adrenocortical carcinoma, adrenal, in children.
Abrasion, mucosal, complication of ureteroscopy, 614-615
161
Alcohol consumption, as risk factor for adult
Abscess, renal, in children, treatment of, 532 renal cell carcinoma, 242
moderation of, for prevention of prostate
Absent abdominal muscle syndrome. See
cancer. 305—306
Prunebell, syndrome
Alendrolate, therapy with, to prevent bone loss in
Access sheaths, urethral, routine use of, cons,
prostate cancer patients, 337-339
83-87
pros, 71-81, 179 Alport hereditary nephritis, hematuria in children
due to, 568—569
Access, for ureteroscopy, current trends in,
183-184 Alternative medicine, for treatment of
techniques for, 61-64 chemotherapy effects in prostate cancer
patients, 374-375
Acinar proliferation, atypical small, as markers
in prevention and treatment of erectile
for risk of development of prostate cancer, 229
dysfunction, acupuncture, 253-255
Acupuncture, for nocturnal enuresis, 504-505 dietary supplements, 250—253, 259-268
for treatment of erectile dysfunction, 253-255
Amifostine (WR-2721), reducing complications of
Acute bacterial cystitis, in children, treatment of, radiotherapy for localized prostate cancer
527-528 with, 362-363
Adhesions, as complication of circumcision, 465 Amputation, as complication of circumcision, 465
Adolescents, varicocele in, 509-515 Anabolic steroids, for prevention and treatment
of erectile dysfunction, 260-262
Adrenal hyperplasia, congenital, prenatal repair
androstenedione, 260-261
of, 394-395
dehydroepiandrosterone (DHEA), 261-262
Adrenal tumors, in children, 607-617
Analgesia, controversy over circumcision and,
adrenocortical carcinoma, 614-615
461-462
neuroblastoma, 613-614
pheochromocytoma, 615 Anatomic considerations, in ureteroscopy, 15-20
pyelocaliceal system, 15—16
Adrenalectomy, robotic, 753-756
ureter, 17-18
current world experience, 754-755
ureteropelvic junction, 16—17
future directions, 755
ureterovesical junction, 18—19
laboratory experience, 753-754
0094-0143/04/$ - see front matter ¢ 2004 ElsevieIrn c All rights reserved
doi:10.1016/S0094-0143(04)00126-0
802 Cumulative Index | Urol Clin \ im 3a17] (2004) 801-824
Ancillary instrumentation, for ureteroscopy. See Apoptosis, markers of, as surrogate endpoints in
Instruments, ancillary prostate cancer prevention, 230-231
Androgen, effect on testicular descent, 470 Arginine, L-, for prevention and treatment of
erectile dysfunction, 259-260
Androgen deprivation therapy, for prostate
cancer treatment, bisphosphenate therapy to Arteriovenous malformations, renal, pediatric,
prevent bone loss due to, 337 7 342 ureteroscopic treatment of, 156
bone evaluation to perform before, 334-336
22 227 Aspergillosis, urinary tract infection in children
minimizing bone loss due to, 336—33
with, treatment of, 533
osteoporosis in men due to, 313-319
Aspirin, as risk factor for adult renal cell
Androgen insensitivity syndrome, male
carcinoma, 240-241
hermaphroditism due to, 438
Atypical small acinar proliferation, as marker of
Androstenedione, for prevention and treatment of
risk for development of prostate cancer, 229
erectile dysfunction, 260-261
Augmented reality, in robotic vision, 793-794
Anesthesia, controversy over circumcision and,
461-462 Automated Endoscopic System for Optimal
for ureteroscopy, 43-47 Positioning (AESOP) system, robotic urologic
sensory innervation of kidney and ureter, surgery using, 655, 661-662, 782-783
43.44
{vena sativa (oats), for prevention and treatment
with local anesthesia and intravenous
of erectile dysfunction, 266
sedation, 44-45
with regional or general anesthesia, 45-46 Avulsion, ureteral, complication of ureteroscopy,
157-158
Angiogenesis, markers of, as surrogate endpoints
in prostate cancer patients, 231 Awakening, lifting and, for nocturnal enuresis in
children, 501
Angiomyolipoma, in children, 612-613
Anorchia, congenital, male hermaphroditism due
to, 439 B
Bacterial cystitis, acute, in children, treatment of,
Antenatal therapy. See Prenatal management
527-528
Antibiotic use, prior to surgical management of
Bacteriology, of pediatric urinary tract infection,
urolithiasis in children, 589-590
517
Anticholinergic treatment, for voiding
Baskets, stone, for retrieval of renal calculi, 54—57
dysfunction, 486-488
Bed-wetting. See Nocturnal enuresis
Antiemetic agents, for treatment of chemotherapy
effects in prostate cancer patients, 374-375 Behavioral treatment, for nocturnal enuresis,
499-507
Antihypertensive drugs, as risk factor for adult
acupuncture, 504-505
renal cell carcinoma, 241
enuresis alarm, 501—504
Antioxidants, as a protective factor against fluid restriction, 501
urologic cancers, 282 hypnotherapy, 504
lifting and night awakening, 50]
Antireflux surgery, laparoscopic, in children,
601-602 retention control training, 501
robotic, in pediatrics, 748-751 Benign familial nephropathy, hematuria in
extravesical antireflux surgery, 748 750 children due to, 569
transvesical antireflux surgery, 750 “41 5]
Benign hematuria. See Hematuria, benign.
Apolipoprotein A-1, as marker for coronary heart
Bioabsorbable materials, for ureteral stents, 5:
disease, 199-201
Biocompatability, of ureteral stent material, 5
Apolipoprotein B, as marker for coronary heart
disease, 199 201 Biodegradable stents, 177
Cumulaiive Index | Urol Clin N Am 31 (2004) 801-824
Biodurability, of ureteral stent material, 52 Bone metastases, from prostate cancer,
‘ bisphosphonate therapy and, in patients with
Biofeedback, in therapy for voiding dysfunction, wag. ‘ Py ‘
486 other druggs for, 346: -34
prevention of bone loss with, 343-346
Biofilm formation, or ureteral stent material, ‘ from prostate cancer, bisphosphonate therapy
. and, in patients with, 342-343
Biomarkers. See Markers, molecular ? patients with, 342-34
Bisphosphonate therapy, in prostate cancer Bone mineral 4 me ad See ee
patients undergoing androgen deprivation treatment on, 322 ‘32 / ;
therapy, for bone loss, 337-342 my eee for determination of,
for bone metastases, 342—343 324-32 ;
for prevention of bone metastases, low, risk factor for osteoporosis, 322
343-345 Bowel program, in therapy for voiding
Bladder cancer, in children, 619-627 dysfunction, 486
hematuria due to, 569 Brachytherapy, for localized prostate cancer,
rhabdomyosarcoma, 619-624 353-366
transitional cell carcinoma, 624 complications associated with, 356
preventive medicine and, potential role of patient selection for, 360—362
cyclooxygenase-2 inhibitors in, 215 reducing risk of complications, 359-360
robotic surgery for, 719-721 using drugs to reduce complications,
Bladder control, developmental aspects of, 362-363
48 1-482
See also Voiding dysfunction Cc
Bladder exstrophy, initial management of, C-flex ureteral stents, 53
e745 C-r-eraecatcitviev e prporotteeiinn , as marmkaerrk er ff or coronary hheeaarrt
anatomy, 418-420 P ‘
: disease, 201
clinical presentation, 418
embryology and pathophysiology, 417-418 Calcium supplements, to minimize bone loss in
incidence and inheritance, 417 prostate cancer patients, 336-337
postoperative care, 423-424
Calcium, coronary, as marker for coronary heart
surgical Management, current techniques, 2
. = disease, 203
422-423
history of, 421-422 Calculi, renal and ureteral, stone baskets for
Bladd botic. for bladd retrieval of, 54—57
adder surgery, robotic, for bladder cancer,
“ ie -* a ureteroscopic treatment of, 89-98
719-721 “Late, , a!
: " history and evolution of techniques for,
port placement for, using da Vinci robot, 7-2 29-90
687 he: .
indications for, 90-93
in pediatrics, 748-751
intrarenal, 130-131
extravesical antireflux surgery, 748-750
results, 95—97
transvesical antireflux surgery, 750-751
techniques for, 67-68, 93-95
Bleeding, as complication of circumcision, 464
: Calyceal diverticulum, flexible ureteroscopy for,
complication of ureteroscopy, 163
133
Bleeding diatheses, as indication for ureteroscopic . .
s ' — 9] P Cancer, adrenal tumors, pediatric, 607-617
treatment of renal calculi, a
. “ . — adrenocortical carcinoma, 614-615
Blood, in urine. See Hematuria neuroblastoma, 613—614
: ' pheochromocytoma, 615
Body-mass index, patient awareness of, in ,
: i ; a 291-293 bladder, robotic radical cystectomy and
revention of prostate cancer, 291-29: sd. :
P P urinary diversion for, B719—729
Bone loss. See also Osteoporosis. bladder, prostate, and testis, pediatric, 619-627
in men with prostate cancer, 331-352 prepubertal testis tumor, 624-626
reasons for increased risk, 331—334 rhabdomyosarcoma, 619-624
804 Cumulative Index N Am 31 (2004) 801-824
Cancer (continued ) common adverse effects, overview, 367-369
transitional cell carcinoma, 624 patient-specific factors, 369
penile, controversy over circumcision and, 463 prevention of toxicity, 372-375
prostate, radical perineal prostatectomy for, toxicity of specific regimens, 369-372
629-641 chemo-hormonal therapy, 372
robotic radical prostatectomy for, docetaxel, 371
European experience with, 693-699 docetaxel plus estramustine, 371
Vattikuti Institute technique for, etoposide plus estramustine, 372
701-717 mitoxantrone plus prednisone, 370-371
renal, pediatric, 607-617 paclitaxel plus estramustine, 371—372
angiomyolipoma, 612-613 three-drug combinations, 372
renal cell carcinoma, 612 risk of urolithiasis in children undergoing,
sarcoma and rhabdoid variant, 612 592-593
Wilms’ tumor, 607-612
Children, ureteroscopy in. See Pediatric
testicular, link with cryptorchidism, 475-476
ureteroscop)
upper tract tansitional cell carcinoma,
ureteroscopic management of, 115-128, Chlamydia, urinary tract infection in children
132-133 with, treatment of, 530
Candidiasis, urinary tract infection in children Cholesterol, non-high-density lipoprotein, as
with, treatment of, 533 marker for coronary heart disease, 199-201
total serum, as marker for heart disease,
Carboplatin, toxicity of, in prostate cancer
~ 195-198
treatment, 370
correlation between prostate cancer and,
Cardiovascular disease, as risk factor for adult 209-210
renal cell carcinoma, 242 patient awareness of, in prevention of
correlation with prostate cancer, 207-212 prostate cancer, 290-291
background, 208-209 reduction of through lifestyle changes,
recent studies of, 209-210 effect on erectile dysfunction, 249-250
patient awareness of risk of, in prevention of
Chordae, as complication of circumcision, 465
prostate cancer, 290-291
hypospadias and, 447
prevention of, impact on men’s health,
195-198, 199-205 Circumcision, male neonatal, 461-467
most common markers of, 195-197 complications, 464-465
potential and emerging markers of, controversies, 461-463
199-203 anesthesia/analgesia, 461-462
malignancy and, 463
Cardiovascular health, and prevention of erectile
risk for urinary tract infection, 461
dysfunction, 249-250
sexual function, 462-463
patient awareness of, in prevention of prostate
sexually transmitted diseases and, 463
cancer, 290-291
indications and contraindications,
Cell-cycle regulators, markers of, as surrogate 463-464
endpoints in prostate cancer prevention, phimosis, 463-464
230-231 urinary tract infection, 464
Chemo-hormonal therapy, toxicity of, in prostate Clodronate, therapy with, to prevent bone loss in
cancer treatment, 372 prostate cancer patients, 338, 342, 344, 346
Chemoprevention, of prostate cancer, studies of Coffee consumption, as risk factor for adult renal
potential markers for, 227-235 cell carcinoma, 242
atypica! intraepithelial lesions, 228-229
Coil retention, of ureteral stent material, 52
molecular markers as surrogate endpoints,
230-232 Collecting system obstruction, as indication for
ureteroscopic treatment of renal calculi
Chemotherapy, for prostate cancer, prevention
associated with, 91-92
and management cf complications of, 367-378
Cumulative Index Urol Clin \ im 31 (2004) 801-824
Complementary medicine, for treatment of androgen influence, 469
chemotherapy effects in prostate cancer homeobox (HOX) genes, 471
patients, 374—375 INSL3/GREAT genes, 470-471
in prevention and treatment of erectile other factors, 471
dysfunction gonadal development and, 47]
acupuncture, 253-255 hypospadias and, 447
dietary supplements, 250-253, 259-268 laparoscopic diagnosis of, 595-596
long-term prognosis, 475-477
Complications, associated with radiotherapy for
fertility, 476-477
localized prostate cancer, 353-366
testicular malignancy, 475-476
of ureteroscopy, 157-171
treatment, 473-475
early postoperative, 165—167
hormonal therapy, 473-474
intraoperative, 157-165
surgical treatment, 474-475
late postoperative, 167-178
nonpalpable testis, 475
Computed tomography, quantitative, screening palpable testis, 474-475
for osteoporosis with, 323, 324, 327 techniques, 476
virtual ureteroscopy using, 30-31 undescended testis histology, 47i
Computer-assisted image analysis, malignancy- yclooxygenase-2 (COX-2) inhibitors, potential
associated changes on, as markers in role of in prevention of urologic conditions,
prevention of prostate cancer, 231—232 368, 369, 370
Computer-integrated surgical systems, ‘ystectomy, robotic radical, in bladder cancer
development of, 672-673 management, 719-729
Conformal radiotherapy, three-dimensional, for ystic fibrosis, urolithiasis in children with, 592
localized prostate cancer, reducing
‘ystic renal disease, hematuria in children due to,
complications of, 357-358
569
Congenital anomalies, urologic, initial
‘ystinuria, urolithiasis due to, in children,
management of, bladder exstrophy, 417-426
581-582
intersex, 435-443
myelomeningocele, 427-434 ystitis, in children, treatment of, acute bacterial,
posterior urethral valves, 399-415 527-528
prunebelly syndrome, 399-415 viral, 528
prenatal management of, 389-397
‘ystolithotomy, for urolithiasis in children, 592
Coronary heart disease, correlation with prostate
ystoprostatectomy, robot-assisted radical, in
cancer, 207-212
bladder cancer management, 719-729
background, 208-209
family history of, as risk factor, 196—197 ‘ysts, urachal, laparoscopic resection of, 598
patient awareness of risk of, in prevention
Cytoscopy, fetal, for prenatal management of
of prostate cancer, 290-291
hydronephrosis, 392-393
prevention of, impact on men’s health,
195-198, 199-205 D
most common markers of, 195-197 Da Vinci surgical system, robotic urologic surgery
potential and emerging markers of, using, 655, 662-665, 784
199-203
Damiana (Turnera diffusa), for prevention and
recent studies of, 209-210
treatment of erectile dysfunction, 266-267
Cost savings, of not placing stent after
Death, as complication of circumcision, 464
ureteroscopy, 175
Deformities, body, as indication for ureteroscopic
Cryptorchidism, 469-480
treatment of renal calculi, 91
diagnosis, 471-473
epidemiology, 469 Dehydroepiandrosterone (DHEA), for prevention
etiology, 469-471 and treatment of erectile dysfunction, 261-262
Cumulative Index | Uro Cli i \ {fm 31] (2004) 801-824
Desmopressin, for nocturnal enuresis, 494-495 Diverticula, urethral, as complication of
use with enuresis alarm, 503 504 hypospadias repair, 457-458
Dexamethasone, toxicity of, in prostate cance! Docetaxel, toxicity of, in prostate cancer
a
treatment, 368 treatment, 368, 370, 3 l
in regimen with estramustine, 371
Diabetes mellitus, as risk factor for adult renal cell
carcinoma, 242 Doxorubicin, toxicity of, in prostate cancer
complications of radiotherapy for localized treatment, 368, 369, 370, 372
prostate cancer in men with, 36]
Dual-energy x-ray absorptiometry (DEXA),
patient awareness of risk of, in prevention of
screening for osteoporosis with, 323, 324-327
prostate cancer, 290-291
Diagnostic ureteroscopy. See also Ureteroscop)
intrarenal, 129-130 E —
techniques for, 67 Echinococcosis, urinary tract infection in children
with, treatment of, 533—534
Diet, lifestyle changes for prevention of prostate
cancer, fiber in, 301-302 Electrocautery, ureteroscopic endopyelotomy
fish in, 304 305 with, 102—103
for weight loss, 293-294 =ndocrine factors, hypospadias due to, 445-446
fruits and vegetables in, 302
soy and other plant estrogens in, 302-304 endopyelotomy, in pediatric patients, 155
unsaturated fats in, 294-296 retrograde. See Retrograde ureteroscopi
low-fat, as protective factor against urologic endopyelotom)
cancers, 282 “endoscope manipulators, development of, in
Dietary supplements, prevention and treatment of robotic urologic surgery, 676
erectile dysfunction using, 250-253, 259-268 =ndoscopes See also | reteroscopes
anabolic steroids, 260-262 advances in, 34
{vena sativa (oats), 266 first flexible, role in evolution of ureteroscopy,
damiana, 266-267 6—7
ginko biloba, 262
endothelin-1, for bone complications related to
impact of and regulations for, 250-251
prostate cancer, 347
interactions with drugs and procedures,
9
¢ndoureterectomy, in pediatric patients, 154-155
Korean red ginseng, 262-264
-nterobiasis, urinary tract infection in children
L-arginine, 259-260
with, treatment of, 528, 530
placebo effects of, 25
quality control, 251 =nuresis alarm, for nocturnal enuresis in children,
Tribulus terrestris, 266 501-504
yohimbine, 264 factors affecting response to, 502-503
zinc, 264-266 in combination with other treatments, 503
multicomponent interventions, 503
Digital imaging, for ureteroscopy, advances in,
with desmopressin, 503-504
34.37
and video documentation and editing, Enuresis, nocturnal, behavioral treatments,
36-37 499-507
digital enhancement and filter medical management, 491-498
technologies, 36
Environmental factors, hypospadias due to, 446
image capture, 34-35
video endoscopy, 35—36 Epididymitis, urinary tract infection in children
with, treatment of, 530
Dilation, for ureteroscopy, techniques for, 64
Epithelial lesions, atypical, of prostate, as markers
Dilation products, for ureteroscopy, 57
for risk of prostate cancer development,
Diurnal enuresis, 483 IIR 999
umulative Index | Urol Clin 4m 31] (2004) 801-824
Equipment malfunction, complication of improving accuracy of delivery of,
ureteroscopy, 163—165 358-359
intensity-modulated, 358
Erectile dysfunction, prevention and treatment of,
patient selection for, 360—362
249-257, 259-273
reducing complications associated with,
acupuncture for, 253-255
357-359
combining prescription drugs and
three-dimensional conformal, 357-358
supplements, 267-268
using drugs to reduce complications,
impact of and regulations for, 250-25]
362-363
interactions with drugs and procedures, 252
Korean red ginseng, 262 264 Externally draining stent, as alternative to
L-arginine, 259-260 internal stent, 178
lifestyle changes for, 249-250
Extracorporeal shock wave therapy, in children,
placebo effects of, 252-25 3
590, 591
quality control, 251
use of ureteroscopy for renal stones after
Tribulus terretris, 266
failed, 90
using dietary supplements, 250-253,
259-268 Extravasation, complication of ureteroscopy,
anabolic steroids, 260—262 161-163
{vena sativa (oats), 266
damiana, 266—267
ginko biloba, 262
alse passage, complication of ureteroscopy,
yohimbine, 264
159
zinc, 264-266
ats, unsatrated, in diet, for prevention of
Estramustine, ioxicity of, in prostate cancer
prostate cancer, 294-296
treatment, 368, 370
in chemo-hormonal therapy, 372 emale pseudohermaphroditism, causes of,
in three-drug combinations, 372 435-436
with docetaxel, 371 practical approach to intersex in newborns,
with etoposide, 372 435-443
279
with paclitaxel, 371
‘ertility, effect of obesity on, 277
Estrogen, dietary soy, for prevention of prostate in long-term prognosis of cryptorchidism,
cancer, 302 304 476-477
Etidronate, therapy with, to prevent bone loss in etal therapy, prenatal management of urogenital
prostate cancer patients, 337-339 anomalies, 389-397
congenital adrenal hyperplasia, 394-395
Etoposide, toxicity of, in prostate cancer
hydronephrosis, 390-393
treatment, 368, 369, 370
myelomeningocele repair, 393-394
in regimen with estramustine, 372
obstructive uropathy, 393
in three-drug combinations, 372
Fiber, viscous (soluble) in diet, for prevention of
Exercise, as a protective factor against urologic
prostate cancer, 301-302
cancers, 282-283
recommendations for prevention of prostate Fiberoptics, role in evaluation of ureteroscopy,
cancer, 305-306 5-6
Exogenous causes, male hermaphroditism due to, Fish, in diet, for prevention of prostate cancer,
439 304-305
Exstrophy. See Bladder exstrophy Fistula, urethrocutaneous, as complication of
circumcision, 465
External beam radiotherapy, for localized
complicating surgical repair of hypospadias,
prostate cancer, 353-366
456
common complications due to, 353-356
impotency due to, 356-357 Flexible tip ureteroscopes, evolution of, 8
Cumulative Index Urol Clin \ im 31 (2004) 801-824
Flexible ureteroscopes, 26-29 H
current trends, 182-183 Heart disease, correlation with prostate cancer,
deflection mechanism, 28-29 207-212
history and development of, 6 patient awareness of risk of, in prevention of
image transmission, 26, 28 prostate cancer, 290-291
physical dimensions, 26 prevention of coronary, impact on men’s
tip design, 29 health, 195-198, 199-205
use of ureteral access sheaths with, cons, most common markers of, 195-197
83-87 potential and emerging markers of, 199-203
pros, 71-81
working and irrigation channel, 52 Heel ultrasound, screening for osteoporosis with,
324, 327
Fluid restriction, for nocturnal enuresis in
children, 501 Hemangiomas, in urinary tract, hematuria in
children due to, 570
Fractionated voiding, 483 renal, pediatric, ureteroscopic treatment of, 154
Fruits, in diet, for prevention of prostate Hematuria, benign, ureteroscopy for, 137-143
cancer, 302 pathology, 138-139
patient evaluation, 137 138
G results, 141-142
General anesthesia, for ureteroscopy, 45-46 technique, 139-141
evaluation of in children, 559-573
Genetic factors, hypospadias due to, 446
definitions, 559
Giggle micturition, 484 in specific conditions, 567—57|
with glomerular causes, 567—569
Ginko biloba, for prevention and treatment of
with renal parenchymal causes, 569-570
erectile dysfunction, 262
with urinary tract and vascular infection,
Ginseng, Korean red, for prevention and 570-571
treatment of erectile dysfunction, incidence and prevalence, 559-560
262-264 indications for prompt evaluation, 562-563
initial evaluation, 560-562
Glanduloplasty, meatal advancement and, for
macrohematuria, differential diagnosis and
hypospadias, 449-45]
management, 563-564
Glomerular causes, of hematuria in children, microhematuria, differential diagnosis,
567-569 564-565
management, 565-567
Glomerulonephritis, hematuria in children due to,
pathophysiology, 560
postinfectious, 567-568
rapidly progressive, 568 Henoch-Schonlein purpura, hematuria in children
due to, 568
Gonadal dysgenesis, practical approach to, in
newborns, 436 a1 i Hermaphroditism, true, approach to in newborns,
437-438
Gonadectomy, laparoscopic, in children, 598
Hermes system, robotic urologic surgery with, 661
Gonadotropin-releasing hormone stimulation
test, to identify varicocele in adolescents, 512 Hernia, inguinal, hypospadias and, 447
laparoscopic diagnosis of, 596
Growth factors, for prevention and
laparoscopic repair of, in children, 600-601
treatment of toxicity during prostate
cancer treatment, 373-374 High-definition video systems, for ureteroscopy.
37-38
Guidewires, for ureteroscopy, 49-51
shaft rigidity, 51 High-density lipoprotein (HDL), as marker for
size, 50 heart disease, 195-198
surface coating, 50-51 patient awareness of, in prevention of prostate
tip design, 50 cancer, 290-291
Cumulative Index Urol Clin \ 4mm 31 (2004) 801-824
Hinman syndrome, 483 chordae and, 44
epidemiology, 446-447
Histology, of undescended testis, 471
etiology, 445-446
History, of robotic urologic surgery, 653 presentation, 448
671-672, 781-782 surgical repair, 448-456
for radical prostatectomy, 693-694 complications, 456-458
of ureteroscopy, evolution and progress in, for distai, 449-452
5-13 for middle and proximal, 452-456
durability of flexible ureteroscopes,
fiberoptics, 5-6
first flexible endoscope, 6
flexible tip ureteroscopes, 8 Idiopathic urethrorrhagia, hematuria in children
due to, 571
in pediatrics, 9
intraluminal lithotripsy, 9-11 IgA nephropathy, hematuria in children due to,
rigid ureteroscopes, 7—8 568
semirigid ureteroscopes, 9
Illumination, of operative field, in ureteroscopy,
upsizing working channels, 8-9
33 34
Homeobhox HOX genes, cryptorchidism and,
Image analysis, computer-assisted, malignancy-
47]
associated changes on, as marker in prevention
Homocysteine, as marker for coronary heart of prostate cancer, 231—232
disease, 201-202
Image display systems, for ureteroscopy, 37-38
Hormonal factors, as risk factor for adult renal
cell carcinoma, 24? 243 Image guidance, and augmented reality in robotic
vision, 793-794
Hormonal therapy, for cryptorchidism, 473-474
Imaging, digital. See Digital imagir g4
toxicity of, in prostate cancer treatment, 372 .
in screening for osteoporosis, 3 5
Hydatid cyst disease, urinary tract infection in
Imipramine, for nocturnal enuresis, 495
children with, treatment of, 533—534
Impotence, radiation-induced, in men with
Hydronephrosis, prenatal management of,
localized prostate cancer, 356-357
390-393
Incontinence, urinary. See also Voiding
Hypercalciuria, hematuria in children due to,
dysfunction
569-570
stress urinary, obesity-related, 27¢
urolithiasis due to, in children, 577-580
Infection, as complication of circumcision, 464
Hyperoxaluria, urolithiasis due to, in children,
complication of ureteroscopy, 165-166
582-586
urinary tract. See Urinary tract infection
Hypertension, as risk factor for adult renal cell
Inflammation, elimination of, in therapy for
carcinoma, 239-240
voiding dysfunction, 486
as risk factor for heart disease, 196—197
patient awareness of, as risk factor for Inflammatory bowel disease, complications of
prostate cancer, 291 radiotherapy for localized prostate cancer in
men with, 360-361
Hypnotherapy, for nocturnal enuresis, 504
Inguinal hernia, hypospadias and, 447
Hypocalcitraturia, urolithiasis due to,
in children, 586 INSL3/GREAT genes, cryptorchidism and
470-471
Hypospadias, 445-460
as complication of circumcision, 465 Instruments, for ureteroscopy. See also
associated findings, 447-448 Ureteroscopes
cryptorchidism and inguinal hernia, 447 ancillary, 49-59
intersexuality, 447 dilation products, 57
prostatic utricle, 447-448 guidewires, 49-51
810 Cumulative Index Urol Clin \ im 31 (2004) 801-824
Instruments (continued) Kidney disease, pre-existing, as risk factor for
manipulation instruments, 54—57 adult renal cell carcinoma, 238—239
stents, ureteral, 51—54
Kidney injury, as risk factor for adult renal cell
in robotically assisted surgery in pediatric c—ar cinoma,q 2233 90
urology, 745
Kidney operations. See Renal surgery
Intensity-modulated radiotherapy, for
localized prostate cancer, reducing Kidney stones, as risk factor for adult renal cell
complications of, 358 carcinoma, 238
Internet, telemedicine systems and ureteroscopy, Kidney transplantation, ureteroneocystotomy
39-40 strictures after, 111-112
Intersex, hypospadias and, 447 Kidney tumors. See Renal tumors
laparoscopic diagnosis of, 596
Kliinefelter’s syndrome, intersex and, 439
practical approach to in newborn period,
435-443 Korean red ginseng, for prevention and treatment
diagnosis, 435-44] of erectile dysfunction, 262-264
female pseudohermaphroditism,
435-436
gonadal dysgenesis, 436-437
male pseudohermaphroditism, 437-439 L-Arginine, for prevention and treatment of
sex chromosome anomalies, 439-44] erectile dysfunction, 259-260
true hermaphroditism, 437
Laparoscopic urologic surgery, for genitourinary
history and physical examination, 441
anomalies in children, 595-605
patient evaluation, 441-442
diagnostics, 595-596
radiographic tests, 442
cryptorchidism, 595-596
Interstitial nephritis, hematuria in children due to, hernia, 596
569 intersex conditions, 596
Intrarenal ureteroscopic procedures, advanced, emerging role of robotic surgery in, 602-603
129-135 extirpative surgery, 596-598
diagnostic flexible ureteroscopy, 129-130 gonadectomy and Mullerian remnants,
598
for calculus disease, 130—132
for calyceal diverticulum, 133 nephrectomy, 596-597
for upper tract tumors, 132-133 - partial nephrectomy, 597-598
urachal cysts, 598
Intravenous sedation. with local anesthesia. for reconstructive surgery, 599-602
ureteroscopy, 43-44
antireflux surgery, 601-602
Intussusception, ureteral, complication of continent diversion and augmentation,
ureteroscopy, 158 602
hernia repair, 600-601
Irrigation, for ureteroscopy, techniques for,
orchiopexy, 599-600
65-66
pyeloplasty, 601
Island onlay procedure, for hypospadias repair, in pelvic floor reconstruction, 763—764
452-453 role of robotics in laparosocpic procedures,
781-792
adrenalectomy, 785
cystectomy, 787
Ketoconazole, toxicity of, in prostate cancer future applications, 789-790
treatment, 370, 372 nephrectomy, 784-785
partial nephrectomy, 785
Kidney, sensory innervation of, 43-44
pediatric applications, 788-789
Kidney cancer. See also Renal cell carcinoma pyeloplasty, 785-786
preventive medicine and, potential role of radical prostatectomy, 786-787
cyclooxygenase-2 inhibitors in, 215 sacrocolpopexy, 787-788